Type 1 Diabetes Treatment beyond Insulin: Role of GLP-1 Analogs
| Autor: | Pablo F. Mora, Gregory O. Clark, Ildiko Lingvay, Lindsay B. Harrison |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Insulin pump medicine.medical_specialty medicine.medical_treatment Hypoglycemia Gastroenterology General Biochemistry Genetics and Molecular Biology Young Adult Insulin Infusion Systems Bolus (medicine) Glucagon-Like Peptide 1 Weight loss Internal medicine Diabetes mellitus Humans Hypoglycemic Agents Insulin Medicine Retrospective Studies Type 1 diabetes business.industry Liraglutide General Medicine Middle Aged medicine.disease Diabetes Mellitus Type 1 Treatment Outcome Endocrinology Female medicine.symptom business Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Investigative Medicine. 61:40-44 |
| ISSN: | 1708-8267 1081-5589 |
| DOI: | 10.2310/jim.0b013e318279b7d6 |
| Popis: | Objective To observe the efficacy and safety of glucagonlike peptide-1 (GLP-1) analogs in type 1 diabetes in a real-life medical practice setting. Methods We performed a retrospective chart review of patients with type 1 diabetes initiated on a GLP-1 analog and with at least one follow-up visit at more than 4 weeks. Results We identified 11 patients who were initiated on a GLP-1 analog and had a follow-up visit between 4 and 13 weeks (mean (SD) follow-up 10 ± 3 weeks; age 36.5 ± 16.4 years; duration of diabetes 17.3 ± 9.3 years; all on insulin pump therapy; all started on liraglutide). Seven of these patients had a second follow-up visit at approximately 20 weeks. By 10 weeks, there was a significant decrease in weight (4.2% of total body weight), total daily insulin dose (19.2%, of which 14.0% basal and 24.1% bolus), and mean (SD) insulin units/kg (0.57 [0.17] to 0.48 [0.17] units/kg). Hemoglobin A1c was significantly decreased (7.4 [0.7%] to 7.0 [0.7%], P = 0.02) without an increase in hypoglycemia. These effects were sustained at 20 weeks. Nausea was a common adverse effect and lead to drug discontinuation in 4 of 11 patients. Conclusions Patients with long-standing type 1 diabetes can achieve weight loss and improved glycemic control on less insulin without an increase in hypoglycemia when liraglutide is added to insulin therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|